Victoria Gamerman’s love of analytics and math came from her grandmother—the first mathematician she knew. And in her nearly decade at Boehringer Ingelheim, she’s been putting that love to use as the Global Head of Data Governance and Insights. In the latest episode of Bio-IT World’s Trends from the Trenches podcast, host Stan Gloss, founder of BioTeam, talks with Gamerman about real world data, why it’s important for drug discovery, and the shifts happening around how we think about data. “Historically what I have seen and observed in terms of industry trends and trends from regulators is… a culture of data collected for a very specific purpose. Therefore, the design of a clinical trial is very specific to address the scientific question at hand,” she says.
Gamerman speaks openly about how shifts in technology help real-world data make a significant impact on precision and public health, the challenges that varied data sources present to scientists, and how those same challenges present useful information regarding a patient’s health journey. “The trifecta of information that ultimately comes out of those data sources is what will give us the huge opportunity to better understand and create really powerful medicines for future generations.”
